Please assess the completion status of the following clinical trial:

Trial Title: Impact of an Immune Modulator Dimethyl Fumarate on Acute Ischemic Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. \>18 y of age;~2. acute onset of focal neurological deficit consistent with acute ischemic stroke;~3. measurable neurological deficit (NIHSS ≥ 5);~4. anterior-circulation ischemic stroke defined by magnetic resonance angiography (MRA) and Diffusion-Weighted Imaging(DWI);~5. onset of symptom to admission more than 4.5 h and less than 72 h. Patients who arrived within 0-4.5 h poststroke were treated with other medications according to the best accepted medical treatment guidelines.~Exclusion Criteria:~1. Other diseases of the central nervous system~2. There has been neurological disability in the past (mRS score\>2)~3. Difficulty swallowing~4. Arrhythmia, atrioventricular block~5. Use of anti-tumor drugs, other immunosuppressive and immunomodulatory drugs~6. Macular edema~7. MRA shows vertebral basilar artery obstruction~8. Hemorrhagic stroke~9. Patients who are known to have hypersensitivity to dimethyl fumarate or any excipients of this product~10. Pregnant and lactating women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- standard management plus Dimethyl Fumarate (Type: EXPERIMENTAL): None
- standard management (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).